SEB Asset Management AB Purchases New Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

SEB Asset Management AB purchased a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 1st quarter, Holdings Channel reports. The firm purchased 245,043 shares of the company’s stock, valued at approximately $11,811,000.

A number of other large investors also recently modified their holdings of GPCR. Sterling Capital Management LLC acquired a new position in Structure Therapeutics in the 1st quarter worth about $28,000. State of Wyoming acquired a new stake in shares of Structure Therapeutics during the second quarter valued at about $28,000. CWM LLC boosted its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after purchasing an additional 449 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Structure Therapeutics during the fourth quarter worth about $127,000. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Wolfe Research began coverage on shares of Structure Therapeutics in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. HC Wainwright decreased their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $110.55.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $46.98 on Tuesday. The business has a 50-day simple moving average of $44.51 and a 200 day simple moving average of $56.30. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The firm has a market capitalization of $3.34 billion, a price-to-earnings ratio of -54.00 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.